Monthly Prescribing Reference | TEVA PHARMACEUTICAL INDUSTRIES LIMITED : FDA Approves Teva's ... 4-traders (press release) TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia ... New Treanda Formulation Approved FDA approves Teva's injectable Treanda |
